Opioid antagonists in the treatment of opioid-induced constipation and pruritus.
OBJECTIVE
To describe the role of opioid antagonists in the treatment of opioid-induced constipation and pruritus.


METHODS
A MEDLINE search was performed (1966-February 2000) for narcotics and opioid antagonists. Results were limited to English-language and clinical trials. Background information was obtained from pharmacology and pharmacotherapy references and review articles. Hand searching of selected bibliographies yielded several references.


METHODS
Studies were reviewed that examined the use of naloxone, naltrexone, and methylnaltrexone for opioid-related constipation and pruritus. Selected citations included various clinical trials and case series.


RESULTS
Opioid agents are used for cancer and nonmalignant pain. Peripheral opioid receptor stimulation due to endogenous (i.e., endorphins) or exogenous (i.e., morphine) stimulants may result in negative adverse effects, including constipation and pruritus. Adjuvant agents, such as laxatives and antihistamines, are often used to treat these adverse effects, but are themselves associated with adverse effects and are sometimes ineffective. Opioid antagonists have demonstrated reversal of peripheral opioid receptor stimulation. Clinical trials show adequate maintenance of pain control, as well as decreases in opioid-induced constipation and pruritus.


CONCLUSIONS
Opioid antagonists offer a therapeutic alternative to conventional adjuvant agents, with the risk of loss of analgesia at higher doses. Methylnaltrexone offers the advantage of peripheral action only, therefore not reversing analgesia. Results are promising; however, larger clinical trials are necessary before opioid antagonists become the standard of care for opioid-induced constipation and pruritus.
Friedman
J D
JD
Drug Information Department, Novo Nordisk Pharmaceuticals, Inc., 100 College Rd. West, Princeton, NJ 08540-6604, USA. jif@nnpi.com
Dello Buono
F A
FA
D002986:Clinical Trials as Topic; D003248:Constipation / Q000139:chemically induced / Q000188:drug therapy*; D006801:Humans; D009020:Morphine / Q000009:adverse effects; D009270:Naloxone / Q000627:therapeutic use; D009271:Naltrexone / Q000031:analogs & derivatives / Q000627:therapeutic use; D009292:Narcotic Antagonists / Q000627:therapeutic use*; D009294:Narcotics / Q000009:adverse effects*; D011537:Pruritus / Q000139:chemically induced / Q000188:drug therapy*; D000644:Quaternary Ammonium Compounds
D009292:Narcotic Antagonists; D009294:Narcotics; D000644:Quaternary Ammonium Compounds; C032257:methylnaltrexone; D009270:Naloxone; D009271:Naltrexone; D009020:Morphine